RE:Dr. Jean-Pierre Bizzarihe shows up on oncy's website under scientific advisory board members. also:
Dr. Jean P. Bizzari, MD, is an Independent Director at Halozyme Therapeutics, Inc., a Chairman at NETRIS Pharma SAS and a President & Director at Synergie Lyon Cancer.
He is on the Board of Directors at Aprea Therapeutics, Inc., ADC Therapeutics SA, Halozyme Therapeutics, Inc., European Organisation for Research & Treatment of Cancer, Oxford BioTherapeutics Ltd., International Drug Development Institute SA and Synergie Lyon Cancer. Dr. Bizzari was previously employed as an Independent Director by Nordic Nanovector ASA, an Independent Director by Valerio Therapeutics SA, an Independent Director by Pieris Pharmaceuticals, Inc., an Independent Director by Celator Pharmaceuticals, Inc., an Executive Vice President & Global Head-Oncology by Celgene Corp., an Independent Director by Transgene SA, a Vice President-Clinical Oncology Development by Sanofi-Aventis Pharmaceuticals, a Vice President-Clinical Development Oncology by Sanofi-Synthelabo, Inc., a Vice President-Clinical Development Oncology by Rhone Poulenc Rorer, a Vice President-Clinical Oncology by Rhne-Poulenc, Inc., a Head-Oncology by Institut de Recherches Internationales Servier, and a Vice President-Clinical Development by Aventis, Inc.
He also served on the board at Compugen Ltd., Theravectys SAS and iTeos Therapeutics SA.
He received his graduate degree from the Uniiversity of Nice Sophia Antipolis and a doctorate degree from the University of Nice Sophia Antipolis.